ACADIA Pharmaceuticals バランスシートの健全性
財務の健全性 基準チェック /66
ACADIA Pharmaceuticalsの総株主資本は$516.7M 、総負債は$0.0で、負債比率は0%となります。総資産と総負債はそれぞれ$914.1Mと$397.4Mです。 ACADIA Pharmaceuticalsの EBIT は$22.8Mで、利息カバレッジ比率-1.1です。現金および短期投資は$500.9Mです。
主要情報
0%
負債資本比率
US$0
負債
| インタレスト・カバレッジ・レシオ | -1.1x |
| 現金 | US$500.94m |
| エクイティ | US$516.70m |
| 負債合計 | US$397.40m |
| 総資産 | US$914.10m |
財務の健全性に関する最新情報
We're Interested To See How ACADIA Pharmaceuticals (NASDAQ:ACAD) Uses Its Cash Hoard To Grow
Mar 27
We're Interested To See How ACADIA Pharmaceuticals (NASDAQ:ACAD) Uses Its Cash Hoard To Grow
Dec 04Recent updates
Acadia Pharmaceuticals: Nuplazid Performs In Q2 While Daybue Disappoints Again
Aug 26The Strong Earnings Posted By ACADIA Pharmaceuticals (NASDAQ:ACAD) Are A Good Indication Of The Strength Of The Business
Aug 14ACADIA Pharmaceuticals Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
Aug 09ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) Price Is Right But Growth Is Lacking
Aug 01Shareholders Will Probably Hold Off On Increasing ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) CEO Compensation For The Time Being
May 23ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) Price Is Right But Growth Is Lacking
Apr 24We're Interested To See How ACADIA Pharmaceuticals (NASDAQ:ACAD) Uses Its Cash Hoard To Grow
Mar 27Acadia Pharmaceuticals: Post Pimavanserin Study Setback Selloff May Continue
Mar 12ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Just Released Its Full-Year Earnings: Here's What Analysts Think
Mar 01Acadia Pharmaceuticals: New Daybue Drug Already Showing Signs Of Slowing
Feb 29Soleno Therapeutics And Acadia Pharmaceuticals: Hope For Prader-Willi Families
Jan 23ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) Share Price Boosted 35% But Its Business Prospects Need A Lift Too
Jan 03We're Interested To See How ACADIA Pharmaceuticals (NASDAQ:ACAD) Uses Its Cash Hoard To Grow
Dec 04Insufficient Growth At ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Hampers Share Price
May 22Acadia Pharmaceuticals: Nuplazid's (Pimavanserin) Last Hurrah
Oct 19FDA accepts Acadia's new drug application for Rett syndrome treatment trofinetide
Sep 12Acadia: Powerful Unfolding Catalysts
Aug 03Acadia Pharma submits marketing application to FDA for trofinetide to treat Rett syndrome
Jul 18FDA AdComm Rejects Nuplazid This Time But Acadia's Race Isn't Run Yet
Jun 29財務状況分析
短期負債: ACADの 短期資産 ( $728.9M ) が 短期負債 ( $337.9M ) を超えています。
長期負債: ACADの短期資産 ( $728.9M ) が 長期負債 ( $59.5M ) を上回っています。
デット・ツー・エクイティの歴史と分析
負債レベル: ACADは負債がありません。
負債の削減: ACAD過去 5 年間負債を抱えていません。
債務返済能力: ACADには負債がないため、営業キャッシュフロー でカバーする必要はありません。
インタレストカバレッジ: ACADには負債がないため、利息支払い の負担は問題になりません。